Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age

Authors not listed

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · 2021

Abstract

Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (3\~17 years old) Research purpose:Main purpose:To evaluate the safety and tolerability of recombinant New Coronavirus vaccine (CHO cells) in healthy people aged 3 to 17. Secondary purpose: To explore the immunogenicity and persistence of recombinant New Coronavirus vaccine (CHO cells) in healthy people aged 3 to 17. Overall design:A single center, randomized, blind, placebo-controlled trial design was adopted. Study population: 75 healthy people aged 3 to 17 years old, both male and female. Test groups: 3 to 5 years old: 20 cases in experimental group and 5 cases in placebo group; 6 to 11 years old: 20 patients in the experimental group and 5 patients in the placebo group; 12 to 17 years old: 20 patients in experimental group and 5 patients in placebo group.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-04 MST

Cite this

APA
Anonymous. (2021). A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age. <em>Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT04961359
Vancouver
Anonymous. A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age. Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. 2021.
BibTeX
@misc{anon2021ARando, title = {A Randomized, Blinded, Placebo-controlled Phase Ⅰ Clinical Trial of Recombinant New Coronavirus Vaccine (CHO Cells) in the Safety and Tolerability of Healthy People Aged 3 to 17 Years of Age}, author = {Anonymous}, journal = {Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.}, year = {2021}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings